enfortumab vedotin,enfortumab
seagen,astellas
['enfortumab', 'urothelial', 'ev-301']
asco 2022 news: updated ev-301 data show that the survival advantage conferred by enfortumab vedotin over standard chemotherapy is maintained over time in pretreated advanced urothelial cancer.
Springer Healthcare IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.